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Xie et al. in their article entitled “sleep dri-
ves metabolite clearance from the adult
brain” in Science (342: 373–377) (1),
provide an important insight into the
potential physiology behind the restora-
tive and homeostatic nature of sleep, a
basic requirement for normal brain func-
tion. This study, utilizing a mouse model
explores the clearance of peptides such as
amyloid beta, which is implicated in the
pathogenesis of Alzheimer’s disease (2) and
may offer a platform for the investiga-
tion of other forms of neurodegeneration
associated with other putative neurotoxic
proteins.
Key to understanding their paradigm is
an exploration of the differences between
physiological clearance of cellular waste
from the central nervous system and
peripheral tissues. Systemic waste inter-
stitial proteins are transported via lymph
vessels and the systemic circulation to the
liver for degradation (1). The brain lacks
this mechanism and relies on the recircula-
tion of cerebrospinal fluid, which acquires
waste proteins as it flows through the inter-
stitial spaces surrounding brain cells (2)
before interfacing with the systemic cir-
culation at the arachnoid granulations.
This convective mechanism constitutes the
glymphatic system and relies on aquaporin
4 (AQP4) water channels for effective clear-
ance of waste solute. The authors highlight
that many of the putative proteins associ-
ated with neurodegeneration are found in
the interstitial fluid surrounding brain cells
and that knocking out AQP4 channels for
example reduces the clearance of amyloid
beta (Aβ) by 65% (1).
Xie et al. used a mouse model, with an
implanted cannula for delivery of a fluores-
cent tracer via the cisterna magna into the
CSF, to observe real-time movement of CSF
in vivo using two-photon imaging (1). This
technique allowed the influx of CSF into
the murine cerebral cortex to be monitored
“real-time” in three states; sleep, awake, and
anesthetized.
Electrocorticography (ECoG) and elec-
tromyography (EMG) determined sleep-
wake status, with a sleep state practically
defined as an increased power of slow waves
and an awake state associated with a rela-
tive reduction in slow waves and increase
in power of fast waves (1).
On entering sleep there was a “robust
influx” of fluorescent CSF tracer along the
periarterial spaces, subpial region, and into
the brain parenchyma (1). Sleep was con-
firmed by the presence of a high power of
slow waves on the ECoG.
On awakening, CSF tracer influx
reduced dramatically by 95% (1). The state
of wakefulness was confirmed by a change
in the ECoG (1).
These results were replicated in a cohort
of mice, examined firstly whilst awake. The
intracisternal infusion of fluorescent CSF
tracer was associated with only minimal
influx into the brain. Then on induction
of anesthesia there was a rapid influx of
CSF tracer along the periarterial spaces into
the brain parenchyma, similar to naturally
sleeping mice (1).
They postulate that CSF influx into
brain parenchyma is not simply a function
of arterial pulsation and blood pressure
but rather the interstitial space volume is
dynamic and contracts during wakefulness
and expands during sleep (1).
To test this, they used the real-time
iontophoretic tetramethylammonium
(TMA+) method whereby TMA+ was
delivered via an iontophoresis microelec-
trode in the vicinity of a TMA+-sensitive
microelectrode stationed approximately
150µm away in the interstitial space. In the
paradigm a small interstitial space results
in reduced TMA+ dilution (as volume of
interstitial space is reduced) after delivery
and thus higher levels of residual TMA+
are detected by the sensing electrode (1)
and vice versa. Essentially they confirmed
that the interstitial space volume fraction
was increased by over 60% in anesthetized
or sleeping mice compared to when they
were awake (1).
Knowing that approximately 65% of
exogenously delivered Aβ is cleared by the
glymphatic system they decided to explore
whether interstitial Aβ is cleared most
efficiently during sleep (1). Radiolabeled
125I-Aβ1–40 was injected into the cortex
of awake mice, sleeping mice, and anes-
thetized mice (1). Brains were examined
for levels of residual 125I-Aβ1–40 between
10 and 240 min after injection and they
established that Aβ was cleared twice as
fast in sleeping and anesthetized mice
compared to awake mice. Furthermore, to
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Table 1 | Summary of four principal experimental methodologies, results, and implications.
Experiment Methods Results Implications
Real-time observation of
CSF influx to cerebral
cortex
Infusion of fluoroscopic CSF tracer via a
cannula implanted into the cisterna magna.
Imaging in vivo using two-photon imaging
in three states of arousal (awake, asleep,
and under anesthesia)
When asleep: “robust influx” of
fluorescent CSF tracer along the
periarterial spaces, subpial
regions, and parenchyma
Interstitial space volume is dynamic
and a function of the state of arousal
whether that be physiological states
such as sleep or wakefulness or
artificially induced states such as
anesthesia
When awake: CSF influx reduced
“dramatically” by 95%
When anesthetized: on induction
there was a rapid influx of CSF
similar to the sleeping state
Assessment of interstitial
space volume during
different states of arousal
(sleep, wakefulness, or
anesthesia)
Iontophoretic Tetramethylammonium
method (TMA+): TMA+ delivered to cortex
via an iontophoresis microelectrode
situated 150µm from a TMA+ sensitive
microelectrode located in the interstitial
space
Interstitial space volume fraction
increased by over 60% during
the sleeping or anesthetized
state
Confirms that interstitial space volume
is dynamic and influenced by state of
arousal
Assessment of Aβ
clearance during different
states of arousal (sleep,
wakefulness, or
anesthesia)
Radiolabeled 125I-Aβ1–40 injected into the
cerebral cortex. Brains harvested between
10 and 240 min after injection and residual
125I-Aβ1–40 measured
Aβ cleared twofold faster in
sleeping/anesthetized mice
compared to awake mice
Suggests that glymphatic efflux of
waste interstitial proteins is responsive
to changes in arousal state (both
physiological states such as sleep and
wakefulness and induced states such
as anesthesia)
Determining if interstitial
space volume is influenced
by arousal state or
circadian rhythm
Based on the premise that wakefulness is
driven by noradrenergic tone, glymphatic
tracer influx was assessed (after the local
administration of adrenergic antagonist)
using the fluoroscopic tracer method
outlined above. Furthermore, interstitial
space volume was assessed in response to
noradrenergic antagonist using the
iontophoretic TMA+ method outlined above
Adrenergic antagonist induced
an increase in CSF tracer influx
“more comparable” to that seen
in the sleeping/anesthetized
state than that seen during
wakefulness. Adrenergic
antagonist resulted in significant
increase in interstitial space
volume fraction
Adrenergic tone has a role in
modulating arousal state and the
volume of the interstitial space
account for additional receptor-mediated
clearance of Aβ across the blood brain bar-
rier, an inert 14C-inulin tracer was shown
to be cleared more than twice as fast in
sleeping and anesthetized mice compared
to awake mice (1).
There are two possible contributory fac-
tors. Either interstitial space volume is
influenced by circadian rhythm or it is
a function of the sleep-wake state of the
individual (1). The authors assert that it
is sleep-wake state rather than circadian
rhythm that is fundamental as induction
of anesthesia at a time usually associ-
ated with natural wakefulness results in
identical interstitial space volume and Aβ
clearance to that found in natural sleep
(1). Based on this premise, they postu-
late that the noradrenergic (NA) system
controls the interstitial space volume by
driving arousal. Thus, they hypothesized
that blockade of NA during wakefulness
would result in an increase in CSF influx
into the brain. Xie et al. infused an adren-
ergic antagonist into the cisterna magna
during wakefulness whilst measuring CSF
influx using their original fluorescent CSF
tracer method and found that the infu-
sion of adrenergic antagonists increased
CSF influx similar to that seen in the
sleeping state (1). Using the TMA+ ion-
tophoresis method they further confirmed
that NA antagonism increased the brain
interstitial volume in a similar fashion to
sleep and anesthesia (1). The four princi-
pal experiments by Xie et al. (summarized
in Table 1) have elucidated how cortical
CSF influx and interstitial space volume
are influenced by arousal state and how
pharmacological intervention in the form
of anesthesia or adrenergic antagonism can
modify these parameters.
Why do we need to sleep? The authors
postulate that sleep is the homeostatic
method responsible for the clearance of
toxic metabolic byproducts accumulated
during wakefulness. This study by Xie
et al. raises many questions in the study
of neurodegeneration. Could NA antag-
onists impact on the accumulation of
putative toxic proteins in Alzheimer’s dis-
ease and other forms of neurodegenera-
tion? Is rapid eye movement (REM) sleep
disorder merely a manifestation of alpha
synucleinopathies or could it be implicated
in pathogenesis? Why do some patients
with Parkinson’s disease derive sleep ben-
efit? What causes fluctuating arousal
in dementia with Lewy bodies (DLB)?
Does sleep-wake state influence volumetric
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analysis in MRI? Given the invasive nature
of the experimental methodologies used
they could not be reproduced in humans
in their current format, however they could
provide a platform for the investigation
of clearance of other neurotoxic proteins
involved in neurodegeneration, using a
Parkinson’s disease mouse model for exam-
ple. Furthermore, they may be useful for
investigation of potential drugs to pro-
mote the clearance of neurotoxic proteins,
whether they be currently used adrenergic
antagonist drugs or novel agents. When we
try to encourage a good nights sleep for our
patients perhaps we are doing them more
good than we thought.
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